Merck goes in deeper with Keytruda/Lynparza combo; PureTech unveils stem cell therapy startup
→ Merck is opening up a new wing of its Keytruda pipeline, devoting it to a slate of new Phase III combination studies with Lynparza in treating prostate cancer. Researchers spotted anti-tumor activity in 3 cohorts, sending them the signal they were looking for to pile on pivotal studies in search of a new market. “These promising data presented at ASCO GU coupled with the significant unmet medical need in patients with metastatic castration-resistant prostate cancer, propelled us to initiate three new Phase 3 trials to further evaluate these KEYTRUDA combination regimens,” noted Merck’s Roy Baynes.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.